PRIMARY STUDY

Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease

Key Findings:  Azelnidipine showed significantly better renoprotection in hypertensive patients with mild chronic kidney disease (CKD) over amlodipine. This action is due to it's anti-oxidative effect resulting in lower urinary protein excretion, urinary 8-OHdG, and urinary L-FABP levels.